Health Care · Services-Commercial Physical & Biological Research

MEDP Medpace Holdings Inc SEC Filings & Insider Trading Activity 2026

company
CIK 166839798 filings

MEDP at a glance

Medpace Holdings Inc (MEDP, SEC CIK 1668397) filed its latest 10-K annual report on February 10, 2026, a 10-Q quarterly report on October 22, 2026, an 8-K current report on October 21, 2026 and Form 4 insider filings as recently as November 2, 2026. SignalX summarizes each filing with AI and tracks the company's insider trades and institutional holders.

  • For the fiscal year ended December 31, 2025 (FY2025), Medpace Holdings Inc (MEDP) reported revenue of $2.5 billion (up 20.0% from FY2024) and net income of $451.1 million. Diluted EPS was $15.28.
  • As of September 30, 2026, 39 institutional investment managers tracked by SignalX reported holding Medpace Holdings Inc (MEDP) shares worth $7.3 billion in 13F-HR filings.
  • The most recent insider open-market sale reported on Form 4 was by EWALD STEPHEN P on October 29, 2026 of 1,245 shares at $690.00 per share.
  • In the last 90 days, MEDP insiders reported 0 open-market purchases ($0) and 19 open-market sales ($147.2M) on Form 4, a net sale of $147.2M.

Source: SEC EDGAR (XBRL financial data, 13F-HR and Form 4 filings).

Revenue · FY2025
$2.5B
+20.0% vs prior year
Insiders · 90 days
0 buys · 19 sells
Net −$147.2M
13F holders
39 funds
$7.3B · +0 vs prior quarter
Latest 8-K
Oct 21, 2026
Item 8.01 · Item 2.02

AI 10-K Annual Report Analysis

Latest 10-K, fiscal year ended Dec 31, 2025

Full analysis →

Business Overview

  • Full-service Phase I-IV CRO, serving biotech, pharmaceutical and medical device companies across major therapeutic areas
  • ClinTrak-enabled clinical trial management, integrating real-time study metrics with operating procedures
  • Expanded laboratory platform: four Central Laboratory locations across the U.S., Belgium, China and Singapore
  • Strategic positioning toward small and mid-sized biopharma, emphasizing disciplined execution, therapeutic expertise and timely delivery
  • Customer risk-sharing arrangements, including strategic investments, flexible payment terms and fee financing capabilities

Management Discussion & Analysis

  • Revenue $2.530B, up 20.0% YoY, driven by Metabolic, Oncology and Central Nervous System activity
  • Operating margin 21.1% vs 21.2%, net income $451.1M vs $404.4M
  • Best performing areas: Metabolic, Oncology and Central Nervous System, supporting revenue growth
  • Operating cash flow $713.2M, capex 1.24% of revenue, share repurchases $912.9M, no indebtedness
  • Outlook: organic growth and selective bolt-on acquisitions, with liquidity sufficient for 12 months, but future cash flow and borrowing availability uncertain

Risk Factors

  • Customer concentration: top ten customers generated approximately 35.1% of 2025 net revenue
  • Small-biopharma exposure: 82% of 2025 net revenue came from customers potentially constrained by limited capital
  • Fixed-fee contract overruns: majority of Phase I-IV contracts expose Medpace to underpricing and unrecovered costs
  • Operational dependency: ClinTrak and third-party laboratories, logistics providers, drug depots and contract personnel support service delivery
  • AI disruption: inadequate generative-AI controls could cause delays or errors in customer offerings

AI summary of the MEDP 10-K filed . Generated from the filing text; verify against the original.View on SEC EDGARHow to read a 10-K

AI 10-Q Quarterly Report Analysis

Latest 10-Q, quarter ended Sep 30, 2026

Management Discussion & Analysis

  • Revenue $716.0M, up 8.5% YoY from $659.9M, driven by Metabolic, Oncology and CNS
  • Operating margin 23.1% vs 21.5% YoY, based on operating income of $165.5M and revenue of $716.0M
  • Best-performing therapeutic areas: Metabolic, Oncology and CNS, with no individual revenue figures disclosed
  • Cash $705.3M vs $497.0M at December 31, 2025, operating cash flow $530.4M for nine months
  • Nine-month share repurchases $294.7M, with $527.0M authorization remaining; new $1.0B authorization approved October 20, 2026

Risk Factors

  • No significant changes from the December 31, 2025 Form 10-K risk factors
  • Carried-forward risks include operational, regulatory, competitive, market, and financial exposures disclosed in the 2025 Form 10-K

AI summary of the MEDP 10-Q filed . Generated from the filing text; verify against the original.View on SEC EDGAR10-K vs 10-Q vs 8-K

AI 8-K Current Report Analysis

The most recent material events, by 8-K item

Filed Oct 21, 2026Full analysis →

Item 8.01: Other Events

  • Prior authorization terminated October 20, 2026, with $527.0 million unused
  • New $1.0 billion repurchase authorization runs through December 31, 2028

Item EX-99.1: Item EX-99.1

  • Q3 revenue $716.0M, up 8.5%, with net new awards $873.4M, up 10.6%, supporting continued demand
  • Backlog $3.167B, up 5.6%, but 23.8% conversion rate highlights reliance on execution and timing

Item 2.02: Results of Operations and Financial Condition

  • Q3 and nine-month 2026 financial results announced for periods ended September 30, 2026
  • Press release available as Exhibit 99.1, containing the detailed operating and financial figures
Filed Jul 22, 2026Full analysis →

Item 2.02: Results of Operations and Financial Condition

  • Q2 and first-half 2026 financial results announced for periods ended June 30, 2026
  • Full earnings release available in Exhibit 99.1, containing the detailed operating and financial results

Item EX-99.1: Item EX-99.1

  • Q2 revenue $707.3M, up 17.2%, with backlog conversion rate 24.1%
  • Net new awards $795.7M, up 28.2%, producing 1.13x book-to-bill and supporting future revenue

AI summaries of MEDP 8-K current reports filed with the SEC. What 8-K item codes mean

SignalX for MEDP

Don't miss the next MEDP filing

  • Alerts as it files. A push when MEDP files an 8-K or an insider trades.
  • Fund moves. Which tracked funds opened, added or cut MEDP, by share count.
  • Ask anything. An AI agent that reads every MEDP filing and answers with sources.

MEDP alerts on your phone. Follow it in the SignalX Android app.

Get it on Google Play

Recent Insider Transactions (Form 4)

Latest reported trades by officers, directors and 10% owners

InsiderTypeDatePrice
EWALD STEPHEN PSellOct 29, 2026$690.00
BURWIG SUSAN ESellOct 27, 2026$677.00
BURWIG SUSAN ESellOct 26, 2026$677.00
BURWIG SUSAN EMOct 26, 2026-
BURWIG SUSAN EMOct 26, 2026$166.73
BURWIG SUSAN EMOct 21, 2026$166.73
BURWIG SUSAN EMOct 21, 2026-
BURWIG SUSAN EMOct 12, 2026$166.73

Financial Summary
XBRL

Annual financial summary from SEC XBRL data
MetricFY2023FY2024FY2025
Profitability
Revenue-$2.1B$2.5B
Operating Income-$446.9M$534.9M
Net Income$282.8M$404.4M$451.1M
Op. Margin-21.2%21.1%
Net Margin-19.2%17.8%
Balance Sheet
Total Assets$1.7B$2.1B$2.0B
Equity-$825.5M$459.1M
ROE-49.0%98.3%
Per Share
EPS$8.88$12.63$15.28
Cash Flow
Operating CF-$608.8M$713.2M
CapEx$36.6M$36.5M$31.4M

Source: XBRL data in Medpace Holdings Inc (MEDP)'s 10-K filings on SEC EDGAR, in USD. Compare across companies →

13F Fund Holdings: Quarterly Trend

Latest: Q3 2026

Aggregate MEDP share value held by 13F filers tracked by SignalX, by quarter.

Quarterly totals table
MEDP shares held by 13F filers tracked by SignalX, by quarter
QuarterFundsTotal value
Q3 202639$7.28B
Q2 202639$6.64B
Q1 202641$5.29B
Q4 202537$6.19B
Q3 202537$5.68B
Q2 202533$3.47B
Q1 202530$2.68B
Q4 202426$2.54B
Position changes: Q2 2026 → Q3 2026
Top Buyers
Top Sellers

Source: 13F-HR filings on SEC EDGAR (aggregated from 282 fund-quarter rows). Reflects only 13F filers tracked by SignalX, not the full institutional ownership universe. How 13F filings work

MEDP filing archive

AI analysis pages for each 10-K, 10-Q and 8-K

10-K annual reports

10-Q quarterly reports

Latest 2026 SEC Filings: 10-K, 10-Q, 8-K & Form 4

FormFiling dateAnalysisSEC
4Nov 2, 2026--
4Oct 28, 2026--
4Oct 23, 2026--
10-QOct 22, 2026Analysis
8-KOct 21, 2026Analysis-
4Oct 14, 2026--
4Oct 9, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 2, 2026--
4Oct 1, 2026--
4Sep 29, 2026--
4Sep 25, 2026--
4Sep 23, 2026--
4Sep 21, 2026--
4Sep 17, 2026--
4Sep 17, 2026--
4Aug 31, 2026--
4Aug 28, 2026--
4Aug 27, 2026--
4Aug 25, 2026--
4Aug 24, 2026--
4Aug 21, 2026--
4Aug 21, 2026--
4Aug 21, 2026--

Related Health Care companies

All Health Care →

MEDP SEC filings: frequently asked questions

Are MEDP insiders buying or selling?

In the last 90 days, Medpace Holdings Inc (MEDP) officers, directors and 10% owners reported no open-market purchases and 19 open-market sales worth $147.2 million by 4 insiders on Form 4. Many insider sales are pre-planned or for taxes, so purchases usually carry more information.

Which institutions hold MEDP stock?

As of September 30, 2026, the largest Medpace Holdings Inc (MEDP) holders among the 13F filers tracked by SignalX were BlackRock ($1.6 billion), AQR Capital Management ($863.2 million), T. Rowe Price Group ($709.2 million), Vanguard Portfolio Management LLC ($677.4 million), Vanguard Capital Management LLC ($627.9 million). 13F-HR reports are filed up to 45 days after each quarter ends.

What was MEDP's revenue in fiscal year 2025?

For the fiscal year ended December 31, 2025 (FY2025), Medpace Holdings Inc (MEDP) reported revenue of $2.5 billion (up 20.0% from FY2024) and net income of $451.1 million. Diluted EPS was $15.28. The figures come from the XBRL data in the 10-K.

What are the main risks in MEDP's latest 10-K?

In the 10-K filed February 10, 2026, Medpace Holdings Inc (MEDP) flagged: Customer concentration: top ten customers generated approximately 35.1% of 2025 net revenue. Small-biopharma exposure: 82% of 2025 net revenue came from customers potentially constrained by limited capital. (AI summary of the Risk Factors section.)

What did MEDP report in its latest 8-K?

Medpace Holdings Inc (MEDP) filed an 8-K on October 21, 2026 reporting Item 8.01 (Other Events) and Item 2.02 (Results of Operations and Financial Condition). Prior authorization terminated October 20, 2026, with $527.0 million unused.

What are the latest MEDP SEC filings?

Medpace Holdings Inc (MEDP) filed its latest 10-K annual report on February 10, 2026, a 10-Q quarterly report on October 22, 2026, an 8-K current report on October 21, 2026 and a Form 4 insider filing on November 2, 2026.

What is MEDP's SEC CIK number?

Medpace Holdings Inc (MEDP)'s SEC Central Index Key (CIK) is 1668397. EDGAR lists every MEDP filing under that number.

Ask anything about MEDP

The research agent reads MEDP's filings, financials, insider trades and 13F holders, then answers with sources.